Ge Long Hui·2025-10-28 06:51Core Viewpoint - The report from Huaxi Securities indicates that Shenguan Medical's Q3 2025 revenue, net profit attributable to the parent, and net profit excluding non-recurring items were 2.601 billion, 240 million, and 218 million yuan respectively, showing year-on-year growth of 27.71%, 42.11%, and 50.77%, which aligns with expectations [1] Group 1: Financial Performance - Q3 2025 revenue reached 2.601 billion yuan, reflecting a year-on-year increase of 27.71% [1] - Net profit attributable to the parent was 240 million yuan, up 42.11% year-on-year [1] - Net profit excluding non-recurring items was 218 million yuan, representing a 50.77% increase compared to the previous year [1] Group 2: Business Growth and Market Concerns - The high growth in the medical business is attributed to contributions from mergers and acquisitions, while domestic consumer growth is slowing [1] - There are concerns in the market regarding potential impairment risks related to GRI affecting performance, but the company maintains a positive outlook based on medical endorsements and product advantages in cotton [1] Group 3: Future Outlook - In the short term, the hygiene product segment is expected to maintain high growth driven by platforms like Douyin and KA channels [1] - In the medium term, the domestic cotton soft towel and sanitary napkin market is estimated to be around 100 billion and 1000 billion yuan respectively, with the company likely to increase its market share and improve net profit margins [1] - In the long term, the company aims to achieve dual-driven growth from medical and consumer sectors, with the acquisition of GRI expected to enhance net profit margins in the medium to long term, despite limited short-term profit increase [1]